Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,934.00GBp
19 Oct 2018
Change (% chg)

56.00 (+0.95%)
Prev Close
5,878.00
Open
5,902.00
Day's High
5,956.00
Day's Low
5,869.00
Volume
1,815,486
Avg. Vol
1,822,176
52-wk High
6,126.40
52-wk Low
4,544.50

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Recommends Approval Of Shire's Takhzyro
Friday, 19 Oct 2018 

Oct 19 (Reuters) - EU Medicines Agency::TAKHZYRO, DRUG FOR RARE SWELLING DISORDER.EU MEDICINES AGENCY - RECOMMENDS APPROVAL OF ASTRAZENECA'S BEVESPI AEROSPHERE FOR TREATMENT OF COPD.EU MEDICINES AGENCY - MYLAN'S OGIVRI (TRASTUZUMAB) RECEIVED POSITIVE OPINION TO TREAT BREAST AND GASTRIC CANCER.  Full Article

TMSR Holding Says Jiazhen Li Resigned From Position As Co-Chairwoman & Director On Oct. 4
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - TMSR Holding Company Ltd ::TMSR HOLDING COMPANY - ON OCT 4, JIAZHEN LI RESIGNED FROM POSITION AS CO-CHAIRWOMAN & DIRECTOR OF CO EFFECTIVE IMMEDIATELY.TMSR HOLDING COMPANY - LI'S RESIGNATION IS DUE TO PERSONAL REASON AND NOT A RESULT OF ANY DISAGREEMENT WITH CO.TMSR HOLDING CO SAYS EFFECTIVE OCT. 4, CO’S BOARD APPOINTED ZHEYI WANG AS NEW CO-CHAIRMAN AND A DIRECTOR OF THE BOARD - SEC FILING.  Full Article

Astrazeneca Completes Deal With Cheplapharm For Atacand Rights In 28 European Countries
Monday, 1 Oct 2018 

Oct 1 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC ANNOUNCES AGREEMENT WITH CHEPLAPHARM FOR RIGHTS TO ATACAND IN 28 EUROPEAN COUNTRIES COMPLETED.UNDER TERMS OF AGREEMENT, ASTRAZENECA HAS RECEIVED A PAYMENT OF $200 MILLION FROM CHEPLAPHARM.ASTRAZENECA WILL CONTINUE TO MANUFACTURE AND SUPPLY ATACAND AND ATACAND PLUS UNDER A SUPPLY AGREEMENT.A TIME-BOUND PAYMENT OF $10 MILLION AS WELL AS SALES-CONTINGENT MILESTONES WILL ALSO BE PAYABLE.  Full Article

AstraZeneca Says Bydureon Receives Positive EU CHMP Opinion For Exscel Cardiovascular Outcomes Data
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - AstraZeneca PLC ::BYDUREON RECEIVES POSITIVE EU CHMP OPINION FOR EXSCEL CARDIOVASCULAR OUTCOMES DATA.  Full Article

AstraZeneca Says EC Approves Imfinzi For Stage III NSCLC
Monday, 24 Sep 2018 

Sept 24 (Reuters) - AstraZeneca PLC ::EUROPEAN COMMISSION APPROVES AZ'S IMFINZI FOR STAGE III NSCLC.PHASE III PACIFIC TRIAL DEMONSTRATED COMPELLING OVERALL SURVIVAL BENEFIT AND PROGRESSION-FREE SURVIVAL OF MORE THAN 11 MONTHS.  Full Article

AstraZeneca Says EMA Approves Imfinzi For Stage III NSCLC
Monday, 24 Sep 2018 

Sept 24 (Reuters) - AstraZeneca PLC ::EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC.PHASE III PACIFIC TRIAL DEMONSTRATED COMPELLING OVERALL SURVIVAL BENEFIT AND PROGRESSION-FREE SURVIVAL OF MORE THAN 11 MONTHS.  Full Article

Astrazeneca Says Tezepelumab Gets FDA Breakthrough Therapy Status
Friday, 7 Sep 2018 

Sept 7 (Reuters) - AstraZeneca Plc ::TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION.TEZEPELUMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA.ASTRAZENECA'S FIRST BREAKTHROUGH THERAPY DESIGNATION FOR A RESPIRATORY MEDICINE.  Full Article

Tezepelumab Granted Breakthrough Therapy Designation By US FDA
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Amgen Inc ::TEZEPELUMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE TREATMENT OF PATIENTS WITH SEVERE ASTHMA WITHOUT AN EOSINOPHILIC PHENOTYPE.TEZEPELUMAB IS CURRENTLY IN DEVELOPMENT IN PHASE 3 PATHFINDER CLINICAL TRIAL PROGRAM.  Full Article

Biohaven Licenses Novel Myeloperoxidase Inhibitor From Astrazeneca
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN LICENSES NOVEL MYELOPEROXIDASE INHIBITOR FROM ASTRAZENECA.ENTERED AGREEMENT, THROUGH SUBSIDIARY. WITH ASTRAZENECA FOR DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO AZD3241, AN ORAL MPO INHIBITOR.UNDER TERMS OF AGREEMENT, ASTRAZENECA WILL RECEIVE UPFRONT CASH PAYMENT AND SHARES IN BIOHAVEN.ASTRAZENECA AGREED NOT TO PURSUE ADDITIONAL MPO INHIBITORS IT HAS IN EARLY STAGE CARDIOVASCULAR DEVELOPMENT FOR NEUROLOGIC DISEASES FOR 5 YEARS.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY- PLANS TO CONDUCT A PHASE 3 CLINICAL TRIAL OF AZD3241 CANDIDATE FOR TREATMENT OF MULTIPLE SYSTEM ATROPHY.  Full Article

Voluntis, Astrazeneca Extend Partnership In Digital Therapeutics
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - AstraZeneca PLC ::VOLUNTIS EXTENDS PARTNERSHIP WITH ASTRAZENECA IN DIGITAL THERAPEUTICS FOR ONCOLOGY.VOLUNTIS SA - CO, ASTRAZENECA WILL IMPLEMENT A NEW PHASE OF CLINICAL EVALUATION OF THEIR DIGITAL THERAPEUTIC.VOLUNTIS SA - THE DIGITAL THERAPEUTIC IS DESIGNED TO SUPPORT PLATINUM RESISTANT OVARIAN CANCER PATIENTS TREATED WITH COMBINATION OF CEDIRANIB & OLAPARIB.  Full Article

UPDATE 1-Roche scores win in slowing aggressive type of breast cancer

* Trailing rivals, Roche seeking immunotherapy niches (Adds comments from lead study author, details on PD-L1 subgroup)